Neuroone Medical Technologies Stock Performance
| NMTC Stock | USD 1.14 0.10 9.62% |
On a scale of 0 to 100, Neuroone Medical holds a performance score of 6. The company secures a Beta (Market Risk) of -1.01, which conveys a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Neuroone Medical are expected to decrease slowly. On the other hand, during market turmoil, Neuroone Medical is expected to outperform it slightly. Please check Neuroone Medical's rate of daily change, period momentum indicator, as well as the relationship between the skewness and potential upside , to make a quick decision on whether Neuroone Medical's current price movements will revert.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Neuroone Medical Technologies are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating basic indicators, Neuroone Medical exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:3 | Last Split Date 2021-04-01 |
1 | Disposition of tradable shares by Mark Christianson of Neuroone Medical at 1.54 subject to Rule 16b-3 | 10/11/2024 |
2 | For third straight year, Clearinghouse CDFI Secures 60 Million New Markets Tax Credit Allocation | 10/14/2024 |
3 | Disposition of 22 shares by Rosa David A of Neuroone Medical at 1.02 subject to Rule 16b-3 | 10/22/2024 |
4 | NeuroOne Medical Technologies to Present at the 2024 ThinkEquity Conference | 10/24/2024 |
5 | Disposition of 22 shares by Rosa David A of Neuroone Medical at 1.21 subject to Rule 16b-3 | 11/04/2024 |
6 | Disposition of 343 shares by Mark Christianson of Neuroone Medical at 0.99 subject to Rule 16b-3 | 11/08/2024 |
7 | Disposition of 22 shares by Rosa David A of Neuroone Medical at 1.61 subject to Rule 16b-3 | 11/29/2024 |
8 | Neuroone stock hits 52-week low at 0.56 amid market challenges - Investing.com | 12/05/2024 |
9 | NeuroOne Product Revenue Increases 77 percent to 3.5 Million in Fisca | 12/17/2024 |
10 | Q4 2024 Neuroone Medical Technologies Corp Earnings Call Transcript | 12/18/2024 |
11 | Disposition of 4697 shares by Rosa David A of Neuroone Medical at 0.826 subject to Rule 16b-3 | 12/31/2024 |
12 | NeuroOne Announces Virtual Investor Webinar on January 9, 2025 | 01/03/2025 |
13 | Symbol Lookup | 01/06/2025 |
| Begin Period Cash Flow | 5.3 M |
Neuroone |
Neuroone Medical Relative Risk vs. Return Landscape
If you would invest 91.00 in Neuroone Medical Technologies on October 10, 2024 and sell it today you would earn a total of 23.00 from holding Neuroone Medical Technologies or generate 25.27% return on investment over 90 days. Neuroone Medical Technologies is currently generating 0.5675% in daily expected returns and assumes 6.4307% risk (volatility on return distribution) over the 90 days horizon. In different words, 57% of stocks are less volatile than Neuroone, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neuroone Medical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neuroone Medical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neuroone Medical Technologies, and traders can use it to determine the average amount a Neuroone Medical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0882
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NMTC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.43 actual daily | 57 57% of assets are less volatile |
Expected Return
| 0.57 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average Neuroone Medical is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neuroone Medical by adding it to a well-diversified portfolio.
Neuroone Medical Fundamentals Growth
Neuroone Stock prices reflect investors' perceptions of the future prospects and financial health of Neuroone Medical, and Neuroone Medical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neuroone Stock performance.
| Return On Equity | -3.49 | ||||
| Return On Asset | -1.43 | ||||
| Operating Margin | (3.38) % | ||||
| Current Valuation | 27.17 M | ||||
| Shares Outstanding | 30.84 M | ||||
| Price To Earning | (23.53) X | ||||
| Price To Book | 34.52 X | ||||
| Price To Sales | 8.18 X | ||||
| Revenue | 3.45 M | ||||
| Gross Profit | (3.05 M) | ||||
| EBITDA | (11.84 M) | ||||
| Net Income | (12.32 M) | ||||
| Cash And Equivalents | 10.18 M | ||||
| Cash Per Share | 0.63 X | ||||
| Total Debt | 260.16 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 13.42 X | ||||
| Book Value Per Share | 0.11 X | ||||
| Cash Flow From Operations | (11.01 M) | ||||
| Earnings Per Share | (0.52) X | ||||
| Market Capitalization | 32.08 M | ||||
| Total Asset | 5.37 M | ||||
| Retained Earnings | (75 M) | ||||
| Working Capital | 2.42 M | ||||
| Current Asset | 94.49 M | ||||
| Current Liabilities | 18.26 M | ||||
About Neuroone Medical Performance
By analyzing Neuroone Medical's fundamental ratios, stakeholders can gain valuable insights into Neuroone Medical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Neuroone Medical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Neuroone Medical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 364.74 | 403.88 | |
| Return On Tangible Assets | (150.49) | (142.97) | |
| Return On Capital Employed | 0.84 | 0.88 | |
| Return On Assets | (20.23) | (21.25) | |
| Return On Equity | 1.00 | 1.05 |
Things to note about Neuroone Medical Tec performance evaluation
Checking the ongoing alerts about Neuroone Medical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neuroone Medical Tec help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neuroone Medical Tec is way too risky over 90 days horizon | |
| Neuroone Medical Tec may become a speculative penny stock | |
| Neuroone Medical Tec appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 3.45 M. Net Loss for the year was (12.32 M) with loss before overhead, payroll, taxes, and interest of (3.05 M). | |
| Neuroone Medical Technologies currently holds about 10.18 M in cash with (11.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.63. | |
| Neuroone Medical Tec has a frail financial position based on the latest SEC disclosures | |
| Roughly 16.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: Symbol Lookup |
- Analyzing Neuroone Medical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neuroone Medical's stock is overvalued or undervalued compared to its peers.
- Examining Neuroone Medical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neuroone Medical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neuroone Medical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neuroone Medical's stock. These opinions can provide insight into Neuroone Medical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Neuroone Stock analysis
When running Neuroone Medical's price analysis, check to measure Neuroone Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuroone Medical is operating at the current time. Most of Neuroone Medical's value examination focuses on studying past and present price action to predict the probability of Neuroone Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuroone Medical's price. Additionally, you may evaluate how the addition of Neuroone Medical to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |